A double-blind, randomised, placebo-controlled study in 45 women with pregnancy
gingivitis showed that supplementation of L. reuteri Prodentis significantly
reduced inflammation and plaque compared to placebo.
“Our study shows that L. reuteri containing lozenges may be a valuable adjunct
in the control of pregnancy gingivitis”, says Professor Ulrich Schlagenhauf,
Department of Periodontology, University Hospital Würzenburg, Germany.
45 healthy women with pregnancy gingivitis were enrolled at the beginning of
their third trimester. Participants were randomly provided with a supply of
lozenges to be consumed twice daily until birth (approximately three months),
each containing 5 x10^8 cfu of L. reuteri Prodentis or an equivalent placebo. At
the end of the intervention period both gingival index and plaque index of the
probiotics group were significantly (p < 0.0001) lower than in the placebo
group.
Pregnancy gingivitis
Pregnancy causes hormonal changes that increase the risk of developing
gingivitis (inflammation of the gums). Half of all pregnant women will
experience pregnancy gingivitis. Research have suggested that women with
pregnancy gingivitis may be more likely to deliver babies prematurely or with
low birth weight than mothers with healthy gums.
”Brushing, flossing and seeing a dentist during pregnancy maintains oral health
and may decrease the risk of adverse pregnancy complications. Our study shows
that L. reuteri lozenges may be a valuable new tool in the control of pregnancy
gingivitis”, says Professor Schlagenhauf.
“BioGaia’s products are popular among mothers around the world who use them for
their children throughout childhood. We can now build on this success and offer
products also for mothers-to-be to maintain their oral health during pregnancy
and thereby give their babies the best opportunities for a good start in life”,
says Axel Sjöblad, Managing Director, BioGaia.
The study was published in Journal of Clinical
Periodontology (http://onlinelibrary.wiley.com/doi/10.1111/jcpe.12606/abstract)
27 July 2016.
Latest press releases from BioGaia
2016-05-26 Rights issue in IBT fully subscribed – BioGaia’s underwriting
guarantee will not be utilized
2016-05-17 BioGaia’s probiotic effective in treating abdominal pain in children
2016-05-11 Annual General Meeting of BioGaia
This information is information that BioGaia AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above, at 10.00
CET on 8 August 2016.
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-
enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm.
www.biogaia.com.
BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A,
Stockholm Telephone: +46 8 555 293 00, Corp. identity no. 556380
-8723. www.biogaia.com.
